- Home
- HLP vs AARD Comparison
HLP vs AARD Comparison
Compare HLP & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HLP | AARD |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | China | United States |
| Employees | N/A | 40 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 85.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | HLP | AARD |
|---|---|---|
| Price | $1.16 | $7.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | ★ 3.5M | 250.4K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $51.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $3.35 |
| 52 Week High | $1.72 | $17.94 |
Technical Indicators
Market Signals| Indicator | HLP | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 78.39 | 72.90 |
| Support Level | $0.88 | $4.81 |
| Resistance Level | $1.19 | $11.37 |
| Average True Range (ATR) | 0.13 | 0.77 |
| MACD | 0.08 | 0.19 |
| Stochastic Oscillator | 91.25 | 88.45 |
Price Performance
Historical ComparisonAbout HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.